Madison, WI — Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. [Read more…]
New “Placental Tissue Amendment” Bill Clarifies Disclosures Required to Perform Stem Cell Therapies in Utah
The “Placental Tissue Amendment Bill”, Part of SB 0199, Has Been Passed by the Utah State Legislature.
The “Placental Tissue Amendment Bill“, part of SB 0199, recently passed by the Utah State Legislature, introduces specific requirements for healthcare providers administering treatments involving placental stem cells. The key focus of this bill is to ensure that patients receive adequate disclosures regarding the nature of the treatment, particularly if it involves stem cell therapy that hasn’t been approved by the United States Food and Drug Administration (FDA). [Read more…]
Novo Holdings to Acquire the CDMO Catalent for a Staggering $16.5 Billion Enterprise Value
Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
COPENHAGEN, Denmark and SOMERSET, N.J. – February 5, 2024– Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced that they entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. [Read more…]
Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project
Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance between senescence and cell growth
DALLAS, Texas, March 06, 2024 – Colossal Biosciences, the world’s first de-extinction company, announced that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough. This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation. [Read more…]
2024 HEALinc Future Health Summit to Convene Experts in Longevity and Regenerative Health
Over April 28-30th, 2024, on Paradise Island in The Bahamas, the 2024 HEALinc Future Health Summit will be convening experts from across the fields of longevity, cellular medicine, and regenerative health. The event will bring together the world’s top scientists, investors, healthcare providers, longevity tech companies, and stem cell companies. By attending, you will be positioned to learn about cutting-edge future health medicines and technologies that can support peak performance at any age. [Read more…]
- « Previous Page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- …
- 334
- Next Page »